XOMA ROYALTY is a biotechnology royalty aggregator. The company acquires the potential future economics associated with pre-commercial therapeutic candidates which have been licensed to pharmaceutical or biotechnology companies. XOMA ROYALTY, formerly known as XOMA Corporation, is based in EMERYVILLE, Calif.
| Revenue (Most Recent Fiscal Year) | $52.15M |
| Net Income (Most Recent Fiscal Year) | $31.71M |
| PE Ratio (Current Year Earnings Estimate) | 46.07 |
| PE Ratio (Trailing 12 Months) | 99.26 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 10.77 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.35 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 73.12 |
| Pre-Tax Margin (Trailing 12 Months) | 69.85% |
| Net Margin (Trailing 12 Months) | 53.46% |
| Return on Equity (Trailing 12 Months) | 12.56% |
| Return on Assets (Trailing 12 Months) | 4.11% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.59 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.59 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.96 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.77 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.17 |
| Earnings per Share (Most Recent Fiscal Year) | $0.66 |
| Diluted Earnings per Share (Trailing 12 Months) | $1.57 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 12.54M |
| Free Float | 11.43M |
| Market Capitalization | $522.84M |
| Average Volume (Last 20 Days) | 0.11M |
| Beta (Past 60 Months) | 0.88 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 95.92% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |